"Physicians should be concerned about the increased risk of gallbladder or biliary disease associated with GLP-1 RA use, especially at the higher doses recommended for weight loss," the authors write
When administered at doses of 0, 0.1, 0.25, and 0.5 ug/mL, growth hormone receptor expression was increased in a dose-dependent manner
Patrick Blatchford, MD, FACS brings you the latest advancements in weight loss
However, given the close association between obesity and OSA, as well as the effectiveness of other forms of weight loss in combating OSA, incretin-based therapies hold promise as a therapeutic option for the management of obesity-related OSA
In experimental settings, it is explored for its influence on circadian rhythms, cortisol modulation, and central nervous system balance
doi: 10.2337/dc13-2817 80 Debray-SachsMCarnaudCBoitardCCohenHGresserIBedossaPet al